Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Luke Sergott has maintained an Overweight rating on Twist Bioscience (NASDAQ:TWST) and increased the price target from $40 to $45.
May 03, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Luke Sergott maintains an Overweight rating on Twist Bioscience and raises the price target from $40 to $45.
The increase in price target by Barclays, a reputable financial institution, signals a strong confidence in Twist Bioscience's future performance. This endorsement is likely to positively influence investor sentiment and could lead to a short-term increase in TWST's stock price. The Overweight rating further emphasizes the analyst's positive outlook on the stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100